OmniAb, Inc.
Emma Cahill has a diverse work experience in various scientific and administrative roles. Emma currently works at OmniAb, Inc. as an Associate Scientist since November 2022. Prior to that, they worked at Icagen as an Associate Scientist from August 2021 to November 2022. Emma gained research experience as an Undergraduate Researcher at the University of Notre Dame from May 2019 to May 2021, where they focused on detecting ovarian cancer and studying protein interactions. Emma also worked as a Student Assistant at the University of Notre Dame's Hesburgh Library from August 2017 to May 2021. Additionally, they worked as a Summer Receptionist at Innovations Salon from May 2017 to August 2020 and as a Market Research Intern at Straight North from May 2018 to August 2018.
Emma Cahill attended St. Ignatius College Prep from 2013 to 2017 for their secondary education. Emma then went on to study at the University of Notre Dame from 2017 to 2021. While at Notre Dame, Emma pursued a major in Biochemistry and supplemented it with a Classics major focusing on Latin.
This person is not in any offices
OmniAb, Inc.
The OmniAb discovery platform provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable discovery of next-generation therapeutics. At the heart of the OmniAb platform is the Biological Intelligence (BI) of our proprietary transgenic animals, including OmniRat,OmniChicken and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur features unique structural attributes of cow antibodies for complex targets. OmniAb animals comprise the most diverse host systems available in the industry and they are optimally leveraged through computational antigen design and immunization methods, paired with high-throughput microfluidic-based single B cell screening and deep computational analysis of next-generation sequencing datasets to identify fully human antibodies with superior performance and developability characteristics. An established core competency focused on ion channels and transporters further differentiates our technology and creates opportunities to further leverage across modalities, including antibody-drug conjugates and others. The OmniAb suite of technologies and differentiating computational capabilities and BI features are combined to offer a highly efficient and customizable end-to-end solution for the growing discovery needs of the global pharmaceutical industry. For more information, please visit www.omniab.com.